Pathogenesis of abdominal aortic aneurysms: MicroRNAs, proteases, genetic associations

Annual Review of Medicine

Volumn 65, Issue , 2014, Pages 49-62

  Maegdefessel, Lars ^a   Dalman, Ronald L ^b   Tsao, Philip S ^b,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

AntagomiRs; Cysteine proteases; Genome wide association studies; Heritability; Metalloproteases; Serine proteases

Indexed keywords

CYSTEINE PROTEINASE; MATRIX METALLOPROTEINASE; MICRORNA; MICRORNA 21; MICRORNA 29B; PROTEINASE; SERINE PROTEINASE;

ABDOMINAL AORTA ANEURYSM; ARTICLE; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

AORTIC ANEURYSM, ABDOMINAL; CYSTEINE PROTEASES; EXTRACELLULAR MATRIX; GENOME-WIDE ASSOCIATION STUDY; HOMEOSTASIS; HUMANS; MATRIX METALLOPROTEINASES; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; SERINE PROTEASES;

EID: 84901492263     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-101712-174206     Document Type: Article

References (83)

1. Golledge J, Norman PE. 2011. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis 217:57-63
2. Pande RL, Beckman JA. 2008. Abdominal aortic aneurysm: populations at risk and how to screen. J. Vasc. Interv. Radiol. 19:S2-8
3. Lederle FA, Johnson GR, Wilson SE, et al. 2001. Abdominal aortic aneurysm in women. J. Vasc. Surg. 34:122-26 (Pubitemid 33660699)
4. Thom T, Haase N, Rosamond W, et al. 2006. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:e85-151
5. Golledge J, Muller J, Daugherty A, et al. 2006. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler. Thromb. Vasc. Biol. 26:2605-13
6. Powell JT, Greenhalgh RM. 2003. Clinical practice. Small abdominal aortic aneurysms. N. Engl. J. Med. 348:1895-901 (Pubitemid 36532316)
7. Mani K, Wanhainen A, Lundkvist J, et al. 2011. Cost-effectiveness of intensive smoking cessation therapy among patients with small abdominal aortic aneurysms. J. Vasc. Surg. 54:628-36
8. Shimizu K, Mitchell RN, Libby P. 2006. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 26:987-94 (Pubitemid 43732102)
9. Ghorpade A, Baxter BT. 1996. Biochemistry and molecular regulation of matrix macromolecules in abdominal aortic aneurysms. Ann. NY Acad. Sci. 800:138-50 (Pubitemid 27028951)
10. McDonald DA. 1968. Regional pulse-wave velocity in the arterial tree. J. Appl. Physiol. 24:73-78
11. Thomas M, Gavrila D, McCormick ML, et al. 2006. Deletion of p47phox attenuates angiotensin II- induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation 114:404-13 (Pubitemid 44264822)
12. Sharma AK, Lu G, Jester A, et al. 2012. Experimental abdominal aortic aneurysm formation is mediated by IL-17 and attenuated by mesenchymal stem cell treatment. Circulation 126:S38-45
13. Harrison SC, Smith AJ, Jones GT, et al. 2012. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur. Heart J. Epub ahead of print
14. Yoshimura K, Aoki H, Ikeda Y, et al. 2005. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat. Med. 11:1330-38 (Pubitemid 41752914)
15. ManningMW, Cassis LA, Daugherty A. 2003. Differential effects of doxycycline, a broad-spectrummatrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 23:483-88 (Pubitemid 36337226)
16. Satta J, Haukipuro K, Kairaluoma MI, et al. 1997. Aminoterminal propeptide of type III procollagen in the follow-up of patients with abdominal aortic aneurysms. J. Vasc. Surg. 25:909-15 (Pubitemid 27227688)
17. Kunieda T, Minamino T, Nishi J, et al. 2006. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation 114:953-60 (Pubitemid 44337139)
18. Ailawadi G, Moehle CW, Pei H, et al. 2009. Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J. Thorac. Cardiovasc. Surg. 138:1392-99
19. LindsayME, DietzHC. 2011. Lessons on the pathogenesis of aneurysm from heritable conditions. Nature 473:308-16
20. Loeys BL, Schwarze U, Holm T, et al. 2006. Aneurysm syndromes caused by mutations in the TGF-beta receptor. N. Engl. J. Med. 355:788-98 (Pubitemid 44285584)
21. Regalado ES, Guo DC, Villamizar C, et al. 2011. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ. Res. 109:680-86
22. van de Laar IM, Oldenburg RA, Pals G, et al. 2011. Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat. Genet. 43:121-26
23. Guo DC, Pannu H, Tran-Fadulu V, et al. 2007. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat. Genet. 39:1488-93 (Pubitemid 350191352)
24. Kloosterman WP, Plasterk RH. 2006. The diverse functions of microRNAs in animal development and disease. Dev. Cell 11:441-50 (Pubitemid 44430905)
25. HuntzingerE, IzaurraldeE. 2011. Gene silencing bymicroRNAs: contributions of translational repression and mRNA decay. Nat. Rev. Genet. 12:99-110
26. Cai X, Hagedorn CH, Cullen BR. 2004. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10:1957-66 (Pubitemid 39557833)
27. Yeom KH, Lee Y, Han J, et al. 2006. Characterization of DGCR8/Pasha, the essential cofactor forDrosha in primary miRNA processing. Nucleic Acids Res. 34:4622-29 (Pubitemid 44567057)
28. Hutvagner G. 2005. Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. FEBS Lett. 579:5850-57 (Pubitemid 41487105)
29. Guo L, Lu Z. 2010. The fate ofmiRNA*strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule? PLoS One 5:e11387.
30. Doench JG, Sharp PA. 2004. Specificity of microRNA target selection in translational repression. Genes Dev. 18:504-11 (Pubitemid 38372808)
31. Lewis BP, Burge CB, Bartel DP. 2005. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15-20 (Pubitemid 40094598)
32. Pillai RS, Bhattacharyya SN, Artus CG, et al. 2005. Inhibition of translational initiation by Let-7 microRNA in human cells. Science 309:1573-76 (Pubitemid 41266485)
33. van Rooij E, Olson EN. 2012. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11:860-72
34. Small EM, Frost RJ, Olson EN. 2010. MicroRNAs add a new dimension to cardiovascular disease. Circulation 121:1022-32
35. van Rooij E, Purcell AL, Levin AA. 2012. Developing microRNA therapeutics. Circ. Res. 110:496-507
36. Mishra PK, Tyagi N, Kumar M, et al. 2009. MicroRNAs as a therapeutic target for cardiovascular diseases. J. Cell. Mol. Med. 13:778-89
37. Pramanik D, Campbell NR, Karikari C, et al. 2011. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 10:1470-80
38. Trang P, Wiggins JF, Daige CL, et al. 2011. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol. Ther. 19:1116-22
39. Lee YS, Dutta A. 2009. MicroRNAs in cancer. Annu. Rev. Pathol. 4:199-227
40. Jazbutyte V, Thum T. 2010. MicroRNA-21: from cancer to cardiovascular disease. Curr. Drug Targets 11:926-35
41. Cheng Y, Zhang C. 2010. MicroRNA-21 in cardiovascular disease. J. Cardiovasc. Transl. Res. 3:251-55
42. Davis BN, Hilyard AC, Lagna G, et al. 2008. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454:56-61 (Pubitemid 351931982)
43. Ji R, Cheng Y, Yue J, et al. 2007. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ. Res. 100:1579-88 (Pubitemid 46897261)
44. Sarkar J, Gou D, Turaka P, et al. 2010. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am. J. Physiol. Lung Cell. Mol. Physiol. 299:L861-71
45. Chapman GB, Durante W, Hellums JD, et al. 2000. Physiological cyclic stretch causes cell cycle arrest in cultured vascular smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 278:H748-54
46. Cheng WP, Wang BW, Chen SC, et al. 2012. Mechanical stretch induces the apoptosis regulator PUMA in vascular smooth muscle cells. Cardiovasc. Res. 93:181-89
47. Li C, Wernig F, Leitges M, et al. 2003. Mechanical stress-activated PKCdelta regulates smooth muscle cell migration. FASEB J. 17:2106-8
48. Song JT, Hu B, Qu HY, et al. 2012. Mechanical stretchmodulates microRNA 21 expression, participating in proliferation and apoptosis in cultured human aortic smooth muscle cells. PLoS One 7:e47657
49. Maegdefessel L, Azuma J, Toh R, et al. 2012. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci. Transl. Med. 4:122ra22
50. van Rooij E, Sutherland LB, Liu N, et al. 2006. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. USA 103:18255-60
51. Boon RA, Seeger T, Heydt S, et al. 2011. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ. Res. 109:1115-19
52. Takagi H, Manabe H, Kawai N, et al. 2009. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis. Interact. Cardiovasc. Thorac. Surg. 9:437-40
53. Pyo R, Lee JK, Shipley JM, et al. 2000. Targeted gene disruption ofmatrixmetalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest. 105:1641-49 (Pubitemid 30390315)
54. Longo GM, Xiong W, Greiner TC, et al. 2002. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110:625-32 (Pubitemid 34988786)
55. Curci JA, Petrinec D, Liao S, et al. 1998. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J. Vasc. Surg. 28:1082- 93 (Pubitemid 28562713)
56. Petrinec D, Liao S, Holmes DR, et al. 1996. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J. Vasc. Surg. 23:336-46 (Pubitemid 26070722)
57. Turner GH, Olzinski AR, Bernard RE, et al. 2008. In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI. Circ. Cardiovasc. Imaging 1:220-26
58. Lu H, Rateri DL, Bruemmer D, et al. 2012. Novel mechanisms of abdominal aortic aneurysms. Curr. Atheroscler. Rep. 14:402-12
59. Pagano MB, Bartoli MA, Ennis TL, et al. 2007. Critical role of dipeptidyl peptidase I in neutrophil recruitment during the development of experimental abdominal aortic aneurysms. Proc. Natl. Acad. Sci. USA 104:2855-60 (Pubitemid 46327969)
60. Shi GP, Sukhova GK, Grubb A, et al. 1999. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J. Clin. Invest. 104:1191-97
61. Sun J, Zhang J, Lindholt JS, et al. 2009. Critical role of mast cell chymase in mouse abdominal aortic aneurysm formation. Circulation 120:973-82
62. Subramanian V, Uchida HA, Ijaz T, et al. 2012. Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice. J. Cardiovasc. Pharmacol. 59:66-76
63. Gong Y, Hart E, Shchurin A, et al. 2008. Inflammatory macrophagemigration requires MMP-9 activation by plasminogen in mice. J. Clin. Invest. 118:3012-24
64. Qian HS, Gu JM, Liu P, et al. 2008. Overexpression of PAI-1 prevents the development of abdominal aortic aneurysm in mice. Gene Ther. 15:224-32 (Pubitemid 351150045)
65. Deng GG, Martin-McNulty B, Sukovich DA, et al. 2003. Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm. Circ. Res. 92:510-17 (Pubitemid 36368663)
66. Uchida HA, Poduri A, Subramanian V, et al. 2011. Urokinase-type plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 31:2845-52
67. Hinterseher I, Tromp G, Kuivaniemi H. 2011. Genes and abdominal aortic aneurysm. Ann. Vasc. Surg. 25:388-412
68. Golledge J, Kuivaniemi H. 2013. Genetics of abdominal aortic aneurysm. Curr. Opin. Cardiol. 28:290-96
69. Wahlgren CM, Larsson E, Magnusson PK, et al. 2010. Genetic and environmental contributions to abdominal aortic aneurysm development in a twin population. J. Vasc. Surg. 51:3-7; discussion 7
70. Linne A, Lindstrom D, Hultgren R. 2012. High prevalence of abdominal aortic aneurysms in brothers and sisters of patients despite a low prevalence in the population. J. Vasc. Surg. 56:305-10
71. Shibamura H, Olson JM, van Vlijmen-Van Keulen C, et al. 2004. Genome scan for familial abdominal aortic aneurysm using sex and family history as covariates suggests genetic heterogeneity and identifies linkage to chromosome 19q13. Circulation 109:2103-8 (Pubitemid 38620219)
72. van Vlijmen-Van Keulen CJ, Rauwerda JA, Pals G. 2005. Genome-wide linkage in three Dutch families maps a locus for abdominal aortic aneurysms to chromosome 19q13.3. Eur. J. Vasc. Endovasc. Surg. 30:29- 35 (Pubitemid 40775129)
73. Merino VF, Todiras M, Mori MA, et al. 2009. Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E. J. Mol. Med. (Berlin) 87:953-63
74. Biros E, Norman PE, Walker PJ, et al. 2011. A single nucleotide polymorphism in exon 3 of the kallikrein 1 gene is associated with large but not small abdominal aortic aneurysm. Atherosclerosis 217:452-57
75. Lillvis JH, Kyo Y, Tromp G, et al. 2011. Analysis of positional candidate genes in the AAA1 susceptibility locus for abdominal aortic aneurysms on chromosome 19. BMC Med. Genet. 12:14
76. Helgadottir A, ThorleifssonG, Magnusson KP, et al. 2008. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet. 40:217-24 (Pubitemid 351171400)
77. Visel A, Zhu Y, May D, et al. 2010. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 464:409-12
78. Biros E, Cooper M, Palmer LJ, et al. 2010. Association of an allele on chromosome 9 and abdominal aortic aneurysm. Atherosclerosis 212:539-42
79. Leeper NJ, Raiesdana A, Kojima Y, et al. 2013. Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler. Thromb. Vasc. Biol. 33:e1-10
80. Elmore JR, Obmann MA, Kuivaniemi H, et al. 2009. Identification of a genetic variant associated with abdominal aortic aneurysms on chromosome 3p12.3 by genomewide association. J. Vasc. Surg. 49:1525-31
81. Gretarsdottir S, Baas AF, Thorleifsson G, et al. 2010. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat. Genet. 42:692-97
82. Bown MJ, Jones GT, Harrison SC, et al. 2011. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am. J. Hum. Genet. 89:619-27
83. Boucher P, Gotthardt M, Li WP, et al. 2003. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 300:329-32 (Pubitemid 36433724)